Berger, A.A.; Sottosanti, E.R.; Winnick, A.; Izygon, J.; Berardino, K.; Cornett, E.M.; Kaye, A.D.; Varrassi, G.; Viswanath, O.; Urits, I.
Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS). Neurol. Int. 2021, 13, 207-223.
https://doi.org/10.3390/neurolint13020022
AMA Style
Berger AA, Sottosanti ER, Winnick A, Izygon J, Berardino K, Cornett EM, Kaye AD, Varrassi G, Viswanath O, Urits I.
Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS). Neurology International. 2021; 13(2):207-223.
https://doi.org/10.3390/neurolint13020022
Chicago/Turabian Style
Berger, Amnon A., Emily R. Sottosanti, Ariel Winnick, Jonathan Izygon, Kevin Berardino, Elyse M. Cornett, Alan D. Kaye, Giustino Varrassi, Omar Viswanath, and Ivan Urits.
2021. "Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)" Neurology International 13, no. 2: 207-223.
https://doi.org/10.3390/neurolint13020022
APA Style
Berger, A. A., Sottosanti, E. R., Winnick, A., Izygon, J., Berardino, K., Cornett, E. M., Kaye, A. D., Varrassi, G., Viswanath, O., & Urits, I.
(2021). Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS). Neurology International, 13(2), 207-223.
https://doi.org/10.3390/neurolint13020022
